Philogen Provides Corporate Update
Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trials Fibromun shows potent activity in last-line glioblastoma in combination with Lomustine The OncoFAP platform shows promising results beyond radio-conjugates Cash & cash equivalents of €107.8M Philogen’s management team will hold a Webinar to discuss the news on November 12th, 2021, at 11:00 EST / 16:00 BST / 17:00 CEST (Please find the link to this [...]